SEC Filing Summary: Enochian Biosciences Inc.
Business Context and Reporting Period
This Form 8-K Current Report was filed by Enochian Biosciences Inc. (not Lunai Bioworks Inc.) on June 8, 2023. The registrant is a Delaware corporation with its principal executive offices in Los Angeles, CA. The filing serves to disseminate a press release issued on the same date.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report is a notification of a press release and does not contain audited or unaudited financial statements.
Material Changes
No material financial changes versus prior periods are detailed in this document. The filing references a press release (Exhibit 99.1) for specific operational or strategic updates, but the content of that release is not included in the provided text.
Guidance, Outlook, and Risks
The filing includes a standard disclaimer stating that the information in Item 8.01 and Exhibit 99.1 is not deemed filed for purposes of Section 18 of the Exchange Act and is not subject to the liabilities of that section. No specific guidance, outlook, or risk factors are enumerated in the body of this 8-K.
Key Facts for Investor Verification
- Verify the content of the press release dated June 8, 2023, referenced as Exhibit 99.1, as the 8-K itself contains no substantive operational details.
- Confirm the correct registrant name is Enochian Biosciences Inc., trading under the symbol ENOB on The Nasdaq Stock Market LLC.
- Note that the filing was signed by Luisa Puche, Chief Financial Officer, on June 8, 2023.
- Be aware that the information in the attached press release is not incorporated by reference into this filing unless expressly stated.